Beehive_BKK的个人主页 - 老虎社区

Beehive_BKK

Beehive_BKK

暂无个人介绍

IP属地：未知

3关注

1粉丝

0主题

0勋章

2021-04-29

เซม

@DWP:$HUMBL Inc.(HMBL)$bleeeeeeding 😪

2021-03-15

🙏🏻

Better Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote>

2021-03-04

Hmmmmm

抱歉，原内容已删除

2021-03-04

👌🏻

Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576882204250083","uuid":"3576882204250083","gmtCreate":1613788868700,"gmtModify":1613789950950,"name":"Beehive_BKK","pinyin":"beehivebkkbeehivebkk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"title":"","htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574652001822174","idStr":"3574652001822174"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"title":"","htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","kind":"news","pubTimestamp":1615771321,"share":"https://www.laohunote.com/m/news/1161179297?lang=zh_CN&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价下跌之后，这两家中国电动汽车制造商的估值仍然很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>2020年电动汽车（EV）制造商的股票加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为全球最大的汽车市场继续在其交通运输领域走向电气化。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增加到500万辆。据研究机构 BloombergNEF 称，到 2030 年，这一数字可能达到 1000 万，到 2040 年将接近 2000 万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：NIO）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个是更好的买入，特别是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>正确的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，全球最大的汽车市场具有巨大的增长潜力。问题是，会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克股票代码：TSLA）在上海建造第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们加起来只交付了 131,000 辆纯电动汽车的一半多一点<b>比亚迪</b>（场外交易：BYDDY）于2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在 2020 年交付了近 44,000 辆汽车，而小鹏汽车的交付量则比 2019 年增加了一倍多，达到 27,041 辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要驱动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>小鹏P7运动轿车自2020年初上市以来，累计交付量已超过2万辆，超过G3紧凑型SUV，成为该公司最受欢迎的车型。这标志着中国电动汽车初创企业交付 20,000 辆汽车的速度最快。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款 ET7 豪华轿车。ET7将于明年初上市，并具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统延伸齐平把手，并在驾驶员接近时自动释放车门的“电子闩锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>为完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者纷纷涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股价分别较 2021 年 1 月的高点下跌了 27% 和 38%，现在是看看哪个可能是更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都还没有盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都很高，但销售额预计会快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS 提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它比小鹏便宜。蔚来还通过其电池更换计划对市场采取了独特的方法，该计划允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借 ET7 进军豪华轿车领域，可能有助于将该公司提升到一个新的水平。2020年，毛利率、毛利润和经营现金流均为正，表明盈利之路指日可待。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望拥有充足的资本来资助计划中的增长努力。截至2020年12月31日，蔚来资产负债表上有65亿美元的现金和现金等价物、受限制现金和短期投资，小鹏汽车约有54亿美元。两家公司可以通过在香港证券交易所上市筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于希望只选择一家控股公司参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，具有很大的波动性。但对于那些能够接受这一点并投资适当部分的人来说，最近股价的下跌有助于使蔚来成为目前比小鹏汽车更好的买入对象。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-15 09:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价下跌之后，这两家中国电动汽车制造商的估值仍然很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>2020年电动汽车（EV）制造商的股票加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为全球最大的汽车市场继续在其交通运输领域走向电气化。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增加到500万辆。据研究机构 BloombergNEF 称，到 2030 年，这一数字可能达到 1000 万，到 2040 年将接近 2000 万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：NIO）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个是更好的买入，特别是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>正确的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，全球最大的汽车市场具有巨大的增长潜力。问题是，会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克股票代码：TSLA）在上海建造第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们加起来只交付了 131,000 辆纯电动汽车的一半多一点<b>比亚迪</b>（场外交易：BYDDY）于2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在 2020 年交付了近 44,000 辆汽车，而小鹏汽车的交付量则比 2019 年增加了一倍多，达到 27,041 辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要驱动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>小鹏P7运动轿车自2020年初上市以来，累计交付量已超过2万辆，超过G3紧凑型SUV，成为该公司最受欢迎的车型。这标志着中国电动汽车初创企业交付 20,000 辆汽车的速度最快。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款 ET7 豪华轿车。ET7将于明年初上市，并具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统延伸齐平把手，并在驾驶员接近时自动释放车门的“电子闩锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>为完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者纷纷涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股价分别较 2021 年 1 月的高点下跌了 27% 和 38%，现在是看看哪个可能是更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都还没有盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都很高，但销售额预计会快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS 提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它比小鹏便宜。蔚来还通过其电池更换计划对市场采取了独特的方法，该计划允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借 ET7 进军豪华轿车领域，可能有助于将该公司提升到一个新的水平。2020年，毛利率、毛利润和经营现金流均为正，表明盈利之路指日可待。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望拥有充足的资本来资助计划中的增长努力。截至2020年12月31日，蔚来资产负债表上有65亿美元的现金和现金等价物、受限制现金和短期投资，小鹏汽车约有54亿美元。两家公司可以通过在香港证券交易所上市筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于希望只选择一家控股公司参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，具有很大的波动性。但对于那些能够接受这一点并投资适当部分的人来说，最近股价的下跌有助于使蔚来成为目前比小鹏汽车更好的买入对象。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏集团"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1,"symbols_score_info":{"NIO":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":2130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"title":"","htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"title":"","htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohunote.com/m/news/1172714394?lang=zh_CN&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-03 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"title":"","htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"title":"","htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","kind":"news","pubTimestamp":1615771321,"share":"https://www.laohunote.com/m/news/1161179297?lang=zh_CN&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价下跌之后，这两家中国电动汽车制造商的估值仍然很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>2020年电动汽车（EV）制造商的股票加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为全球最大的汽车市场继续在其交通运输领域走向电气化。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增加到500万辆。据研究机构 BloombergNEF 称，到 2030 年，这一数字可能达到 1000 万，到 2040 年将接近 2000 万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：NIO）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个是更好的买入，特别是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>正确的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，全球最大的汽车市场具有巨大的增长潜力。问题是，会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克股票代码：TSLA）在上海建造第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们加起来只交付了 131,000 辆纯电动汽车的一半多一点<b>比亚迪</b>（场外交易：BYDDY）于2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在 2020 年交付了近 44,000 辆汽车，而小鹏汽车的交付量则比 2019 年增加了一倍多，达到 27,041 辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要驱动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>小鹏P7运动轿车自2020年初上市以来，累计交付量已超过2万辆，超过G3紧凑型SUV，成为该公司最受欢迎的车型。这标志着中国电动汽车初创企业交付 20,000 辆汽车的速度最快。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款 ET7 豪华轿车。ET7将于明年初上市，并具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统延伸齐平把手，并在驾驶员接近时自动释放车门的“电子闩锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>为完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者纷纷涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股价分别较 2021 年 1 月的高点下跌了 27% 和 38%，现在是看看哪个可能是更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都还没有盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都很高，但销售额预计会快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS 提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它比小鹏便宜。蔚来还通过其电池更换计划对市场采取了独特的方法，该计划允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借 ET7 进军豪华轿车领域，可能有助于将该公司提升到一个新的水平。2020年，毛利率、毛利润和经营现金流均为正，表明盈利之路指日可待。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望拥有充足的资本来资助计划中的增长努力。截至2020年12月31日，蔚来资产负债表上有65亿美元的现金和现金等价物、受限制现金和短期投资，小鹏汽车约有54亿美元。两家公司可以通过在香港证券交易所上市筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于希望只选择一家控股公司参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，具有很大的波动性。但对于那些能够接受这一点并投资适当部分的人来说，最近股价的下跌有助于使蔚来成为目前比小鹏汽车更好的买入对象。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors<blockquote>更好的购买：蔚来与小鹏汽车</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-15 09:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价下跌之后，这两家中国电动汽车制造商的估值仍然很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>2020年电动汽车（EV）制造商的股票加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为全球最大的汽车市场继续在其交通运输领域走向电气化。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增加到500万辆。据研究机构 BloombergNEF 称，到 2030 年，这一数字可能达到 1000 万，到 2040 年将接近 2000 万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：NIO）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个是更好的买入，特别是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>正确的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，全球最大的汽车市场具有巨大的增长潜力。问题是，会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克股票代码：TSLA）在上海建造第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们加起来只交付了 131,000 辆纯电动汽车的一半多一点<b>比亚迪</b>（场外交易：BYDDY）于2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在 2020 年交付了近 44,000 辆汽车，而小鹏汽车的交付量则比 2019 年增加了一倍多，达到 27,041 辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要驱动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>小鹏P7运动轿车自2020年初上市以来，累计交付量已超过2万辆，超过G3紧凑型SUV，成为该公司最受欢迎的车型。这标志着中国电动汽车初创企业交付 20,000 辆汽车的速度最快。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款 ET7 豪华轿车。ET7将于明年初上市，并具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统延伸齐平把手，并在驾驶员接近时自动释放车门的“电子闩锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>为完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者纷纷涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股价分别较 2021 年 1 月的高点下跌了 27% 和 38%，现在是看看哪个可能是更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都还没有盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都很高，但销售额预计会快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS 提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它比小鹏便宜。蔚来还通过其电池更换计划对市场采取了独特的方法，该计划允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借 ET7 进军豪华轿车领域，可能有助于将该公司提升到一个新的水平。2020年，毛利率、毛利润和经营现金流均为正，表明盈利之路指日可待。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望拥有充足的资本来资助计划中的增长努力。截至2020年12月31日，蔚来资产负债表上有65亿美元的现金和现金等价物、受限制现金和短期投资，小鹏汽车约有54亿美元。两家公司可以通过在香港证券交易所上市筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于希望只选择一家控股公司参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，具有很大的波动性。但对于那些能够接受这一点并投资适当部分的人来说，最近股价的下跌有助于使蔚来成为目前比小鹏汽车更好的买入对象。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏集团"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1,"symbols_score_info":{"NIO":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":2130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"title":"","htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574652001822174","authorIdStr":"3574652001822174"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"title":"","htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohunote.com/m/news/1172714394?lang=zh_CN&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-03 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}